An experimental Alzheimer’s drug from Eli Lilly & Co. helped patients in a small trial, the company said Monday, renewing hopes that researchers are closing in on therapies that can fight the disease.
The drug slowed the decline in memory and ability to perform activities of daily living by 32% after 18 months among people who received the therapy compared with those who got a placebo, Lilly said.
Lilly’s drug, named donanemab, met the primary goal of the study, according to the company—a milestone one experimental Alzheimer’s drug after another has failed to reach.
“It’s a big moment for Alzheimer’s patients. There’s hope again,” said Daniel Skovronsky, Lilly’s chief scientific officer.
Lilly shares rose more than 10% in early trading Monday on the New York Stock Exchange. Lilly gave only the highlights of the study results, saying details would follow at a medical meeting and in an article in a peer-reviewed journal.